


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C₁₋₆alkyl or OR⁶;

Y is selected from hydrogen, halogen, CN, nitro, SO₂R³, OR⁴, SR⁴, SOR³, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁶SO₂R³, NR⁶CO₂R⁶, NR⁶COR³, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR⁶ and NR⁶R⁷, S(O)_nR⁶; where n is 0, 1 or 2;

Z is aryl or a ring A, where A is a six membered heterocyclic aromatic ring containing one or more nitrogen atoms or may be a 6,6 or 6,5 fused bicycle containing one or more O, N, S atoms, the aryl or A rings all being optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, OH, SH, nitro, COR⁹, CO₂R⁶, SO₂R⁹, OR⁹, SR⁹, SOR⁹, SO₂NR¹⁰R¹¹, CONR¹⁰R¹¹, NR¹⁰R¹¹, NHSO₂R⁹, NR⁹SO₂R⁹, NR⁶CO₂R⁶, NHCOR⁹, NR⁹COR⁹, NR⁶CONR⁴R⁵, NR⁶SO₂NR⁴R⁵, aryl, heteroaryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, OR⁶, NR⁶R⁷, S(O)_nR⁶ (~~where n is 0, 1 or 2~~), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷.

R¹ and R² independently represent a hydrogen atom, halogen, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or a C₁₋₆alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, NR⁶R⁷, OR⁶, S(O)_nR⁶ (~~where n is 0, 1 or 2~~);

or

R¹ and R² together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR⁶ and itself optionally substituted by one or more C₁-C₃ alkyl or halogen;

R³ represents C₃-C₇ cycloalkyl or C₁₋₆alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, OR⁶ and NR⁶R⁷, S(O)_nR⁶ (~~where n = 0, 1 or 2~~), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

R⁴ and R⁵ independently represent hydrogen, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen,

C₃-C₇ cycloalkyl, OR⁶ and NR⁶R⁷, S(O)_nR⁶ (~~where n = 0, 1 or 2~~), CONR⁶R⁷,
NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

or

R⁴ and R⁵ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)_n (~~where n = 0, 1 or 2~~), NR⁸, and itself optionally substituted by halogen or C₁₋₃ alkyl;

R⁶ and R⁷ independently represents a hydrogen atom or C₁-C₆ alkyl;

R⁸ is hydrogen, C₁₋₄ alkyl, -COC₁-C₄ alkyl, CO₂C₁-C₄alkyl or CONR⁶C₁-C₄alkyl;

R⁹ represents aryl, heteroaryl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, aryl, heteroaryl OR⁶ and NR⁶R⁷, S(O)_nR⁶ (~~where n = 0, 1 or 2~~), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

R¹⁰ and R¹¹ independently represent aryl or heteroaryl, hydrogen, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, aryl, heteroaryl, OR⁶ and NR⁶R⁷, S(O)_nR⁶ (~~where n = 0, 1 or 2~~), CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷;

or

R^{10} and R^{11} together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, $S(O)_n$ (where $n=0, 1$ or 2), NR^8 , and itself optionally substituted by halogen or C_1 - C_3 alkyl.

2. (Currently amended) A compound according to claim 1 in which R^1 and R^2 independently represent a hydrogen atom, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl or a C_{1-6} alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C_3 - C_7 cycloalkyl, NR^6R^7 , OR^6 , $S(O)_nR^6$ (where n is 0, 1 or 2) or R^1 and R^2 together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR^6 and itself optionally substituted by one or more C_1 - C_3 alkyl or halogen;

3. (Currently amended) A compound according to claim 1 [[or 2]] in which X is C_{1-4} alkyl or C_{1-4} alkoxy.

4. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to 3~~ in which Y is hydrogen.

5. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to 4~~ in which Z is phenyl or optionally substituted as defined in claim 1.

6. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to 4~~ in which Z is phenyl or optionally substituted by one or more substituents independently selected from halogen, C_{1-3} alkyl, cyano and SO_2R^9 .

7. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to 6~~ in which R^1 and R^2 are both hydrogen or one is hydrogen and the other is C_{1-3} alkyl.

8. (Currently amended) A compound according to claim 1 ~~any one of claims 1 to 7~~ selected from:

[(5-Methylbiphenyl-2-yl)oxy]acetic acid,

{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy} acetic acid,

{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy} acetic acid,

[[4-Chloro-4'-(ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

[[4'-(Ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,

2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

and pharmaceutically acceptable salts thereof.

9. (Cancelled)

10. (Currently amended) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1 ~~claims 1 to 8~~.

11. (Currently amended) A method of treating a respiratory disease, ~~such as asthma and rhinitis~~, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1 ~~claims 1 to 8~~.

12. (New) The method of claim 11, wherein the respiratory disease is asthma or rhinitis.

13. (New) A compound according to claim 2 in which X is C₁₋₄alkyl or C₁₋₄alkoxy.

14. (New) A compound according to claim 2 in which Y is hydrogen.

15. (New) A compound according to claim 2 in which Z is phenyl or optionally substituted as defined in claim 1.
16. (New) A compound according to claim 2 in which Z is phenyl or optionally substituted by one or more substituents independently selected from halogen, C₁₋₃alkyl, cyano and SO₂R⁹.
17. (New) A compound according to claim 2 in which R¹ and R² are both hydrogen or one is hydrogen and the other is C₁₋₃ alkyl.